Oxford Biomedica signs agreement to acquire ABL Europe

Oxford, UK – 4 December 2023: Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, announces that it has entered into a sale and purchase agreement with Institut Mérieux, for the acquisition of ABL Europe, a Group’s company specialized in viral vector development and manufacturing.